T. Rowe Price Associates’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,465,161
| Closed | -$105M | – | 2991 |
|
|
2023
Q4 | $105M | Buy |
4,465,161
+2,561,460
| +135% | +$45.6M | 0.01% | 535 |
|
|
2023
Q3 | $28.4M | Buy |
1,903,701
+1,809,280
| +1,916% | +$24M | ﹤0.01% | 832 |
|
|
2023
Q2 | $1.03M | Buy |
94,421
+21,810
| +30% | +$203K | ﹤0.01% | 1794 |
|
|
2023
Q1 | $634K | Sell |
72,611
-56,806
| -44% | -$455K | ﹤0.01% | 2006 |
|
|
2022
Q4 | $811K | Sell |
129,417
-45,683
| -26% | -$174K | ﹤0.01% | 1879 |
|
|
2022
Q3 | $613K | Buy |
175,100
+52,900
| +43% | +$190K | ﹤0.01% | 2022 |
|
|
2022
Q2 | $360K | Buy |
122,200
+12,077
| +11% | +$28.8K | ﹤0.01% | 2368 |
|
|
2022
Q1 | $342K | Buy |
110,123
+13,472
| +14% | +$42.4K | ﹤0.01% | 2501 |
|
|
2021
Q4 | $327K | Sell |
96,651
-40,923
| -30% | -$155K | ﹤0.01% | 2566 |
|
|
2021
Q3 | $502K | Hold |
137,574
| – | – | ﹤0.01% | 2386 |
|
|
2021
Q2 | $600K | Buy |
137,574
+68,239
| +98% | +$303K | ﹤0.01% | 2303 |
|
|
2021
Q1 | $315K | Buy |
69,335
+21,377
| +45% | +$115K | ﹤0.01% | 2551 |
|
|
2020
Q4 | $275K | Buy |
47,958
+24,400
| +104% | +$185K | ﹤0.01% | 2455 |
|
|
2020
Q3 | $171K | Buy |
+23,558
| New | +$126K | ﹤0.01% | 2452 |
|
|
2018
Q4 | – | Sell |
-410,967
| Closed | -$4.55M | – | 2602 |
|
|
2018
Q3 | $4.55M | Sell |
410,967
-276,310
| -40% | -$3.43M | ﹤0.01% | 1466 |
|
|
2018
Q2 | $9.22M | Sell |
687,277
-12,823
| -2% | -$160K | ﹤0.01% | 1358 |
|
|
2018
Q1 | $9.09M | Buy |
+700,100
| New | +$8.7M | ﹤0.01% | 1353 |
|
Other funds holding CBAY
T. Rowe Price Associates's CBAY Position: Q1 2024 in Review
T. Rowe Price Associates sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 4,465,161 shares — an estimated $105M sold.
T. Rowe Price Associates first reported a position in CBAY in Q1 2018 and held it in 17 quarters. The position peaked at $105M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- T. Rowe Price Associates reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- T. Rowe Price Associates sold 4,465,161 Cymabay Therapeutics shares in Q1 2024, an estimated $105M.
- T. Rowe Price Associates first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 17 quarters.
- T. Rowe Price Associates's Cymabay Therapeutics position peaked at $105M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.